Todd Bauer - Dissemin

Papers authored by Todd Bauer

This paper was not found in any repository, but could be made available legally by the author.

2017 Kathleen N. Moore

, Hossein Borghaei, David M. O'Malley, Woondong Jeong, Shelly M. Seward, Todd M. Bauer

, Raymond P. Perez, Ursula A. Matulonis, Kelli L. Running, Xiaoyan Zhang, Jose F. Ponte, Rodrigo Ruiz‐Soto, Michael J. Birrer

Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors

Upload

This paper is made freely available by the publisher.

Kathleen N. Moore, Lainie P. Martin, David M. O’Malley, Ursula A. Matulonis, Jason A. Konner, Raymond P. Perez, Todd M. Bauer

, Rodrigo Ruiz-Soto, Michael J. Birrer

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Download from doi.org

Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M. Bauer

, Anna F. Farago, Jennifer J. Wheler, Stephen V. Liu, Robert Doebele, Laura Giannetta, Giulio Cerea, Giovanna Marrapese, Michele Schirru and 20 other authors

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Download from aacrjournals.org

Jesus G. Berdeja, Todd Bauer

, Edward Arrowsmith, James Essell, Patrick Murphy, James A. Reeves, Ralph V. Boccia, William Donnellan, Ian Flinn

Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy

Download from api.wiley.com

Y. J. Bang, G. Giaccone, S. A. Im, D. Y. Oh, T. M. Bauer

, J. L. Nordstrom, H. Li, G. R. Chichili, P. A. Moore, S. Hong, S. J. Stewart, J. E. Baughman, R. J. Lechleider, H. A. Burris

First-in-human Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

Upload

Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer

, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren A. Byers, Melissa L. Johnson, Howard A. Burris, Francisco Robert, Tae H. Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur and 8 other authors

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Upload

2016 Jeffrey R. Infante, Antoine Hollebecque, Sophie Postel-Vinay, Todd M. Bauer

, Elizabeth M. Blackwood, Marie Evangelista, Sami Mahrus, Franklin V. Peale, Xuyang Lu, Srikumar Sahasranaman, Rui Zhu, Yuan Chen, Xiao Ding, Elaine R. Murray, Jennifer L. Schutzman and 3 other authors

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Download from aacrjournals.org

Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick A. Ott, Manish R. Patel, Deborah J. Wong, Gerald S. Falchook, Shubham Pant, Melinda Whiteside, Drew R. Rasco, John B. Mumm, Ivan H. Chan, Johanna C. Bendell, Todd M. Bauer

, Rivka R. Colen and 5 other authors

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

Download from doi.org

Johanna C. Bendell, Todd M. Bauer

, Ruth Lamar, Mathew Joseph, William Penley, Dana S. Thompson, David R. Spigel, Rami Owera, Cassie M. Lane, Chris Earwood, Howard A. Burris

A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors

Download from www.tandfonline.com

David Hong, Jeffrey Infante, Filip Janku, Suzanne Jones, Ly M. Nguyen, Howard A. Burris, Aung Naing, Todd M. Bauer

, Sarina Piha-Paul

, Faye M. Johnson, Razelle Kurzrock, Lisa Golden, Scott Hynes, Ji Lin, Aimee Bence Lin and 1 other authors

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

Download from doi.org

This paper is available in a repository.

A. Drilon, G. Li, S. Dogan, M. Gounder, R. Shen, M. Arcila, L. Wang, D. M. Hyman, J. Hechtman, G. Wei, N. R. Cam, J. Christiansen, D. Luo, E. C. Maneval, T. Bauer

and 14 other authors

What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Download from www.ncbi.nlm.nih.gov

2015 Anna F. Farago, Long P. Le, Zongli Zheng

, Alona Muzikansky, Alexander Drilon, Manish Patel, Todd M. Bauer

, Stephen V. Liu, Sai-Hong I. Ou, David Jackman, Daniel B. Costa, Pratik S. Multani, Gary G. Li, Zachary Hornby, Edna Chow-Maneval and 4 other authors

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Download from www.ncbi.nlm.nih.gov

Tara C. Gangadhar, Omid Hamid, David C. Smith, Todd M. Bauer

, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Thomas F. Gajewski

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

Download from link.springer.com

Garrett M. Frampton, Siraj M. Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M. Bauer

, Mikhail Akimov, Jose A. Bufill, Carrie Lee, David Jentz, Rick Hoover, Sai-Hong Ignatius Ou, Ravi Salgia, Tim Brennan, Zachary R. Chalmers and 23 other authors

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Download from aacrjournals.org